Progenics Pharmaceuticals — Proxy Contest (October 2019)
43 slides from Progenics Pharmaceuticals's proxy contest presentation, Oct 22, 2019
Slide 1: Creating Shareholder Value Through the Advancement of Cancer Treatment
Progenics Creating Shareholder Value Through the Advancement of Cancer Treatment Progenics Find Fight and Follow
Slide 2: Paving the Best Path Forward for Long-Term Shareholder Value
© Her 8D, Come. Cf & a Paving the Best Path Forward for Long-Term eS, Shareholder Value me se, Progenics
Slide 3: Safe Harbor Statements
Safe Harbor Statements Important Information For Investors And Stockholders {esoprowme epson or uteaton ner estes lows sch uscaon no eget scieeaho be made tsb mes oa reps ache eqrenens ecient US Fetes In conmetan wth he Vln cae Slt, routs a tite contr easton statnent and aomsanng WATE cn revcatin ct
Slide 4: Safe Harbor Statements (Cont'd)
Safe Harbor Statements (Cont’d) Cautionary Statement Regarding Forward-Looking Statements row hora facts are forwardioohingstatemers tha ele Pogeics curen pespective of esting ends andinermation sof e dae chs communication and ine sateets regarding Powis Sate an Gpeation lane and delverng aie for st
Slide 5: Executive Summary
® Executive Summary Y The Progenics Board heard the callfor change a the Annual Meeting and has taken major steps to address shareholder feedback The merger agreement with Lantheus reflects the culmination of thoughtful discussions and analysis between Progenics and Lantheus that started at the begi
Slide 6: Executive Summary
———— Sa enn eo .¢ C - Executive Summary Y The combined company would be led by the current Lantheus Board and CEO who have a successful track record generating over 273% in returns for Lantheus shareholders Velan will only be satisfied by taking control of a majority of the Board (paying no control
Slide 7: Lantheus, Progenics Combination Creates a Global Leader in Precision Diagnostics and Therapeutics
Lantheus, Progenics Combination Creates a Global Leader in Precision Diagnostics and Therapeutics Committed to Creating Shareholder Value ¥ Ahighly complementary portfolio of ultrasound and 35% Strong Pro Forma radiopharmaceutical diagnostics and oncology ‘the ti Ownership Stake | _ Financial Profil
Slide 8: Part I: Additional Change Is NOT Warranted
Part I: Additional Change Is NOT Warranted
Slide 9: In July, Shareholders Voted for Minority Change — PGNX Listened and Responded with Immediate Action
————— Sa enn yn ¢ In July, Shareholders Voted for Minority Change — PGNX Listened and « Responded with Immediate Action 2019 AGM ys ———> Today Shareholders Voted for Enhanced Oversight to Drive Sustainable Value and PGNX Took Action sats Progenics ¥ changein Board leadership withthe resignations of
Slide 10: Combination with LNTH Accelerates Strategic Priorities and Creating Shareholder Value
Combination with LNTH Accelerates Strategic Priorities and Creating « Shareholder Value In addition to enhanced oversight, PGNX has continued to execute onits strategic objectives. 2019 Key Mileston ¥ Recorded revenue onitstistcommerialsalesandcompletethefist, ‘Sdministations of commer AZEDRA tntiat
Slide 11: Determined to Take Control, Velan Continues to Make Overstretched Arguments
a 7\ le A z @ 5° Determined to Take Control, Velan Continues to Make Overstretched ¢ Arguments to Seek Disproportional Change e AsGlass Lewis noted, Velon’s “specious suggestons..are healy weighted towards hindsight" Velan's Criticisms PGNX Response Manapeetvas unable sucessfully execute on AZEDRAS
Slide 12: Part II: The LNTH / PGNX Combination Provides the Best Path Forward
Part Il: The LNTH / PGNX Combination Provides the « ; Best Path Forward Offering Substantial and Sustainable \ Value to Shareholders e Sa ‘ fe Progenics or e ) Find Fightan alow”
Slide 13: Creating Substantial Value to Shareholders
Creating Substantial Value to Shareholders 7 359% Lanter emt Compelling Transaction Structure siving equity holders a substantial ~V~ Lantheus to acquire 100% of PGNX's common shares ina tax-free allstock transaction Interest in the combined company ¥PGNX shareholders to receive 0.2502 Lantheus shar
Slide 14: Complimentary Core Capabilities Making a Global Leader
Complimentary Core Capabilities Making a Global Leader Core Capabilities and Infrastructure Management Team Synergies and Cash Flow Generation Progenics Robust oncology therapeutieportfolie with Azedra and 2095 Leading next-generationoncolegy diagnosticin PyL Key strategiepartnerships with Bayer, Ba
Slide 15: The Transaction Provides Greater Value Opportunities for PGNX Shareholders Than as a Standalone Company
The Transaction Provides Greater Value Opportunities for PGNX pw Shareholders Than as a Standalone Company e Value Creation as a Combined Company Progenics as a Standalone Company Identified synergies and cost avoidance amounting to $20mby 2022 and enhanced revenue growth from multiple products "= R
Slide 16: Creating a Well-Balanced Portfolio of Diagnostics to Therapeutics
Creating a Well-Balanced Portfolio of Diagnostics to Therapeutics Precision Diagnostics Oncology Denys peeell eo A QUADRAMET <> sire Teche ‘in v AZEDRA Tati Xenon Xe 133 Gas Trlscnio RELISTOR’ aBsl Gallium pr ostonad etynatrome tome ae F 18 injection Seren oF 18) AzeoRa REUSTOR QUADRAMET Automated B
Slide 17: Announced Premium Inline with or Exceeds All-Stock Precedents
Announced Premium Inline with or Exceeds All-Stock Precedents, with Potential for Future Stock Price Appreciation Remaining Intact 30-Trading Day Share Price Premium Inline with Premium Psidin Comparable llstock Precedents The transacti provides PGNX shareholders with an announced stock premium® inl
Slide 18: Transaction Driving Value for Shareholders
Transaction Driving Value for Shareholders ‘The Transaction Delivers Value to Shareholders Imped Transaction Premium to: 24% 23% aan ice n0% —= — co == em) S2wkintodey igh S2ukeitroday tow 0-raingDey —_—=0-Trxing Day SO Tracing Days ror 30 Tring Day rior. Seven Trading Doy ior Closing Sok ce (uo/as/
Slide 19: Part III: The Transaction Process
Part Ill: The Transaction Process ia é Progenics se gis Ps,
Slide 20: Comprehensive Process to Maximize Shareholder Value
Comprehensive Process to Maximize Shareholder Value Key Points Transaction Timeline Tan." tantheus nd progenies estat the Jp Healncareconfaencetodiniss waystowork together Ongoing discussions began before ary fate s¥BLeerinkontctsaProgencrBcatimembe the dieonofthantheustoerd, oreueranniedutontoMark
Slide 21: Part IV: Shareholders Are Entitled to Full Disclosure on the Transaction
Part IV: Shareholders Are Entitled to Full Disclosure on « ; the Transaction Before Making a Material Decision on aa the Company’s Future e ; 1, 4 Progenics wy » e 2 —) ind Fightand Flow”
Slide 22: Shareholders Should Have Complete Information About the Transaction
———— SSS ern tos Shareholders Should Have Complete Information About the Transaction in Order to Make a Fully Informed Decision About the Composition of Progenics' Board Velan is wrongfully forcing shareholders into making a pivotal decision on the Company's future before allowing shareholders to ha
Slide 23: Part V: Handing Control over to Velan Now Could Lead to Chaos and Value Destruction
Part V: Handing Control over to Velan Now Could Lead to Chaos and Value Destruction Progenics Find Fight and Foltow*
Slide 24: For Velan, Board Control Outweighs Enhancing Value for ALL Shareholders
Nee “wi ” For Velan, Board Control Outweighs Enhancing Value for ALL Shareholders Velan's actions show a lack of concern for other shareholders and aselfindulgent fight for Board control r i saldatreudesa | “ . | Véanmakesmisatingand contacting | Velan has proven they will consider nothing less than
Slide 25: The Argument Against the Transaction Being Approved by Two Resigning Directors is a Red-Herring
——————— eee nr @ 6° The Argument Against the Transaction Being Approved by Two « Resigning Directors is a Red-Herring ¢ The transaction wasunder discussion before Velan’s initial engagement with PGNX Involvement Since Pre-Velan Engagement Both Peter Crowley and Michael Kishbauch, as sitting Director
Slide 26: A Successful Consent Solicitation by Velan Burdens Shareholders with Risk and Uncertainty
————— Sa eenrnrn A Successful Consent Solicitation by Velan Burdens Shareholders with Risk and Uncertainty for the Future If Velan Succeeds in Their Consent Solicitation AND Rejects the Transaction... Unestablished Leadership Lack of Strategy Financial Constraints % Current Board replaced with x Rec
Slide 27: Velan Has Consistently Sought Disproportionate Influence
Velan Has Consistently Sought Disproportionate Influence June, 2019 OFFER REJECTED ‘rogenics Final Settlement Offer Before the AGRA 33% soporezotavein pris, 2019 Api28, 019 Api, 2050, mae “toa merits ting hereto ropes apes tohve mse =. reaconbi srt ot setter mee tO that ny ear adequate stent rere th
Slide 28: Part VI: A Board and Management Team Poised to Create Shareholder Value
Part VI: A Board and Management Team Poised to 5 Create Shareholder Value \e "¢ Progenics Find Fight and Follow”
Slide 29: Highly Experienced and Accomplished Board...
Highly Experienced and Accomplished Board... Pro forma Lantheus + Progenics Board Well-balanced and highly qualified Board Lantheus' Board will remain intact with the addition of Progenics’ independent Director, Bradley Campbell, Director backgrounds are diverse and complementary, bringing together
Slide 30: .. That Delivers Shareholder Value
.. That Delivers Shareholder Value = = Le == _ Ss ‘Mary Anne Heino srai201s, 28708 idl ‘Brian Markison 9/6/2012 27378 i i wv ~ fl 7 oe v v v v ‘Samuelteno- sro 27378 ts - v Julie McHugh 423/2027 181% v a aa of v ean = v v Z v omdin a y v Z Or. FrederickRobertson 9/4/2016 107.9% ci Ca - = we voenesin
Slide 31: The Combined Company Is Led by an Experienced Leadership Team
The Combined Company Is Led by an Experienced Leadership Team John Bolla Chief Operations officer Former VB Supply Chon North America ot GSK ‘among other senior leadership roles ¥ 22 years of diverse supply chen, operations ond ‘manufacturing experience Inthe pharma Inductry Mary Anne Heino Presiden
Slide 32: Combined Board and Corporate Governance Highlights
—————— Sane nr yA ¢ Combined Board and Corporate Governance Highlights ms Board Highlights Corporate Governance Highlights Chairman: Independent Y Ability to call special meetings (50.19%) Board Size: 11 ¥ Ability to approve mergers by majority vote Average Director tenure: 3.1 years) Pro forma Dire
Slide 33: A Combination with Lantheus Accelerates Strategic Priorities Focused on Creating Long-term Shareholder Value
A Combination with Lantheus Accelerates Strategic Priorities Focused « on Creating Long-term Shareholder Value Y Ahighly complementary portfolio of ultrasound and radiopharmaceutical diagnostics and oncology therapeutics Y Diversified revenue streams, enhanced cashflow generation, eliminated future
Slide 34: Shareholders Voted — PGNX Continues to Execute
Shareholders Voted — PGNX Continues to Execute s VF shemoxeiies pod hear ihecaliorGimgestshenrneil vectingand laxeelmemaloemapsto-aiiresshatholder Leihad v ‘The Lantheus transaction reflects the culmination of thoughtful discussion and analysis between Progenics and Lantheus far preceding any engage
Slide 35: Appendix
Appendix
Slide 36: While the Oncology Biopharma Industry Has Experienced Challenges, PGNX Has Performed In-Line with Peers
While the Oncology Biopharma Industry Has Experienced Challenges, PGNX Has Performed Largely In-Line with Peers... 1, 3:, 5-Year TSR to 1-Day Prior to Lantheus Deal Announcement smProny Peer) mmal-ap Onclegy Biopharma) mPGNX eer Year S-Y00r os = (3%) - a7) tom ex 2) wo oo om) rove —<_ =e a vant gw n
Slide 37: Increasing Value Through Synergy and Capital Enhancement
—————— Saas nr ee. Increasing Value Through Synergy and Capital Enhancement Pe Strategi Financial Near Term successful tackrecord of product commerealization Effective Board oversight with strong snced management team with 2 . 1d operational execution commercial, operational and financial expertise
Slide 38: Combination Drives Value Creation Across Multiple Fronts
Combination Drives Value Creation Across Multiple Fronts Transactions atthe forefront ofradlopharma's trajectory ~ combining diagnostics and therapeutics to improve patent care Robust & Complementary Portfolio of Assets Complementary portfolio of ultrasound and radiopharmaceutcal diagnostics and onc
Slide 39: The Transaction Provides a Robust Pipeline with Clear Value Drivers
® The Transaction Provides a Robust Pipeline with Clear Value Drivers Ee dr + wrnienee 2: tenrrenvremaenn lll OCC COOL LLDCS a es Bergen / a te | Sco y SE [ceseecneececeenerrer] es
Slide 40: The Transaction Provides a Strong Financial Outlook
———— Saar een e@ 6° The Transaction Provides a Strong Financial Outlook Pe Increased Gross Margins Accretive to LNTH's EPS Cash Flow Generating Increasing ROIC AHealthy Balance Sheet The transaction puts the combined company in a financ {Gross margin improvement through enhanced revenue growth and r
Slide 41: Endocyte's Sale Price is Not Comparable to Progenics
Endocyte’s Sale Price is Not Comparable to Progenics Given Differences in Probability of Success Driven by POC Data and Phase of Development Endocyte — Enterprise Value (TEV) ce) 1 “noraeesretaratentaio! |1 encoenefotevot ae ' Pane, 1 eSsblion Lo i 1 __sevotgriamaitn HSRC roves satosnounga 758 omen
Slide 42: Termination fee is inline with industry precedents
————————— eer enn e@ 6° Termination fee is inline with industry precedents and not tied to « Progenics shareholder approval ¢ * Company termination fee of $18,340,000is payableit: = Agreementis terminated dueto i) a willful and material violation of the non-solicitor i) Progenics’ board fallsto reco
Slide 43: Peer Groups
Peer Groups asiePharmacestia ne oe sda ne satus Therapeutes Pe Sponored 208 eondoring ne 0m Therapeutics, ne DacphraPhccoutia ne Engle Pharmaceutea ne HarpsonTherepewes ne. denateerapetis, ne ene In Semline Terps ‘oRa Therapies ne syns, ne pues ie ‘oncom harmaceucal in. ge Pharmaceuticals ine sucopo
Progenics Pharmaceuticals — Proxy Contest (October 2019) on 6ix